Core Points - The company has approved the use of idle raised funds for cash management, allowing up to RMB 200 million for investment in financial products [1][14] - The company has successfully redeemed a structured deposit from Chongqing Bank, recovering the principal of RMB 35 million and earning interest of RMB 857,500 [1][2] - The purpose of using idle funds for financial products is to enhance fund efficiency and provide returns to shareholders [2][4] Summary by Sections Investment Management - The company has utilized idle raised funds to purchase structured deposits, specifically the Chongqing Bank Structured Deposit 2025 No. 457, with an investment amount of RMB 35 million [7][9] - The structured deposit is a principal-protected product with floating returns, meeting the criteria for high safety and liquidity [9][10] Fund Sources - The funds used for the financial products are sourced from idle raised funds, which were initially raised through an IPO that generated RMB 842.14 million, netting RMB 790 million after expenses [4][5] Financial Performance - As of June 30, 2025, the company's monetary funds amounted to RMB 1,608.92 million, with the recent investment of RMB 35 million representing 2.18% of the total funds [13][16] - The investment in financial products is not expected to significantly impact the company's future operations or financial status [13][16] Risk Management - The company has established internal controls for managing investment risks, including regular monitoring and audits by the finance department and independent directors [7][10][12] - The company ensures compliance with relevant regulations and maintains transparency in financial disclosures [11][14]
广东丸美生物技术股份有限公司 关于使用闲置募集资金购买理财产品到期赎回并继续购买的公告